UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Congenital neutropenia

Author
Thomas D Coates, MD
Section Editors
Donald H Mahoney, Jr, MD
Laurence A Boxer, MD
Deputy Editor
Alan G Rosmarin, MD

INTRODUCTION

Most cases of neutropenia are acquired and due to increased destruction, granulocyte apoptosis, or decreased granulocyte production. Less common are the congenital neutropenias, which will be discussed here. A general discussion of neutropenia is presented separately. (See "Overview of neutropenia in children and adolescents".)

In addition to the congenital conditions associated with neutropenia presented below, some of these disorders are discussed separately in more detail:

(See "Shwachman-Diamond syndrome".)

(See "Cyclic neutropenia".)

(See "Chediak-Higashi syndrome".)

                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Feb 01 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Donadieu J, Fenneteau O, Beaupain B, et al. Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet J Rare Dis 2011; 6:26.
  2. Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer 2007; 49:609.
  3. Bouma G, Ancliff PJ, Thrasher AJ, Burns SO. Recent advances in the understanding of genetic defects of neutrophil number and function. Br J Haematol 2010; 151:312.
  4. Klein C. Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes. Annu Rev Immunol 2011; 29:399.
  5. Rezaei N, Moazzami K, Aghamohammadi A, Klein C. Neutropenia and primary immunodeficiency diseases. Int Rev Immunol 2009; 28:335.
  6. Welte K, Boxer LA. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol 1997; 34:267.
  7. Zeidler C, Germeshausen M, Klein C, Welte K. Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol 2009; 144:459.
  8. Amato D, Freedman MH, Saunders EF. Granulopoiesis in severe congenital neutropenia. Blood 1976; 47:531.
  9. Leguit RJ, van den Tweel JG. The pathology of bone marrow failure. Histopathology 2010; 57:655.
  10. Boztug K, Rosenberg PS, Dorda M, et al. Extended spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: novel genotypes and phenotypic variability in severe congenital neutropenia. J Pediatr 2012; 160:679.
  11. Dale DC, Bolyard AA, Schwinzer BG, et al. The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. Support Cancer Ther 2006; 3:220.
  12. Donadieu J, Beaupain B, Mahlaoui N, Bellanné-Chantelot C. Epidemiology of congenital neutropenia. Hematol Oncol Clin North Am 2013; 27:1.
  13. Berliner N. Lessons from congenital neutropenia: 50 years of progress in understanding myelopoiesis. Blood 2008; 111:5427.
  14. Dale DC, Link DC. The many causes of severe congenital neutropenia. N Engl J Med 2009; 360:3.
  15. Boztug K, Appaswamy G, Ashikov A, et al. A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med 2009; 360:32.
  16. Klein C, Welte K. Genetic insights into congenital neutropenia. Clin Rev Allergy Immunol 2010; 38:68.
  17. Boztug K, Klein C. Genetic etiologies of severe congenital neutropenia. Curr Opin Pediatr 2011; 23:21.
  18. Klein C, Grudzien M, Appaswamy G, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007; 39:86.
  19. Smith BN, Ancliff PJ, Pizzey A, et al. Homozygous HAX1 mutations in severe congenital neutropenia patients with sporadic disease: a novel mutation in two unrelated British kindreds. Br J Haematol 2009; 144:762.
  20. Faiyaz-Ul-Haque M, Al-Jefri A, Al-Dayel F, et al. A novel HAX1 gene mutation in severe congenital neutropenia (SCN) associated with neurological manifestations. Eur J Pediatr 2010; 169:661.
  21. Xia J, Bolyard AA, Rodger E, et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol 2009; 147:535.
  22. Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006; 108:2182.
  23. McDermott DH, De Ravin SS, Jun HS, et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood 2010; 116:2793.
  24. Lebel A, Yacobovich J, Krasnov T, et al. Genetic analysis and clinical picture of severe congenital neutropenia in Israel. Pediatr Blood Cancer 2015; 62:103.
  25. Boztug K, Järvinen PM, Salzer E, et al. JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nat Genet 2014; 46:1021.
  26. Carlsson G, Aprikyan AA, Tehranchi R, et al. Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells. Blood 2004; 103:3355.
  27. Dale DC. Cyclic and chronic neutropenia: an update on diagnosis and treatment. Clin Adv Hematol Oncol 2011; 9:868.
  28. Xia J, Link DC. Severe congenital neutropenia and the unfolded protein response. Curr Opin Hematol 2008; 15:1.
  29. Köllner I, Sodeik B, Schreek S, et al. Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response. Blood 2006; 108:493.
  30. Dong F, Dale DC, Bonilla MA, et al. Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia 1997; 11:120.
  31. Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000; 96:2317.
  32. Horwitz M, Li FQ, Albani D, et al. Leukemia in severe congenital neutropenia: defective proteolysis suggests new pathways to malignancy and opportunities for therapy. Cancer Invest 2003; 21:579.
  33. Ancliff PJ, Gale RE, Liesner R, et al. Mutations in the ELA2 gene encoding neutrophil elastase are present in most patients with sporadic severe congenital neutropenia but only in some patients with the familial form of the disease. Blood 2001; 98:2645.
  34. Bellanné-Chantelot C, Clauin S, Leblanc T, et al. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood 2004; 103:4119.
  35. Boxer LA, Stein S, Buckley D, et al. Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations. J Pediatr 2006; 148:633.
  36. Horwitz MS, Duan Z, Korkmaz B, et al. Neutrophil elastase in cyclic and severe congenital neutropenia. Blood 2007; 109:1817.
  37. Newburger PE, Pindyck TN, Zhu Z, et al. Cyclic neutropenia and severe congenital neutropenia in patients with a shared ELANE mutation and paternal haplotype: evidence for phenotype determination by modifying genes. Pediatr Blood Cancer 2010; 55:314.
  38. Carlsson G, Melin M, Dahl N, et al. Kostmann syndrome or infantile genetic agranulocytosis, part two: Understanding the underlying genetic defects in severe congenital neutropenia. Acta Paediatr 2007; 96:813.
  39. Germeshausen M, Grudzien M, Zeidler C, et al. Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations. Blood 2008; 111:4954.
  40. Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010; 150:196.
  41. KOSTMANN R. Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. Acta Paediatr Suppl 1956; 45:1.
  42. Kostmann R. Infantile genetic agranulocytosis: A review with presentation of 10 cases. Acta Pediatr Scand 1975; 64:362.
  43. Welte K, Zeidler C. Severe congenital neutropenia. Hematol Oncol Clin North Am 2009; 23:307.
  44. Beekman R, Valkhof MG, Sanders MA, et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 2012; 119:5071.
  45. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81:2496.
  46. Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75:1056.
  47. Carlsson G, Ahlin A, Dahllöf G, et al. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia. Br J Haematol 2004; 126:127.
  48. Zeidler C, Boxer L, Dale DC, et al. Management of Kostmann syndrome in the G-CSF era. Br J Haematol 2000; 109:490.
  49. Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol 2006; 43:189.
  50. Welte K, Dale D. Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol 1996; 72:158.
  51. Donini M, Fontana S, Savoldi G, et al. G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms. Blood 2007; 109:4716.
  52. Yakisan E, Schirg E, Zeidler C, et al. High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome). J Pediatr 1997; 131:592.
  53. Fewtrell MS, Kinsey SE, Williams DM, Bishop NJ. Bone mineralization and turnover in children with congenital neutropenia, and its relationship to treatment with recombinant human granulocyte-colony stimulating factor. Br J Haematol 1997; 97:734.
  54. Takamatsu Y, Simmons PJ, Moore RJ, et al. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 1998; 92:3465.
  55. Zeidler C, Grote UA, Nickel A, et al. Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry. Haematologica 2014; 99:1395.
  56. Zeidler C, Welte K, Barak Y, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 2000; 95:1195.
  57. Ferry C, Ouachée M, Leblanc T, et al. Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register. Bone Marrow Transplant 2005; 35:45.
  58. Carlsson G, Winiarski J, Ljungman P, et al. Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatr Blood Cancer 2011; 56:444.
  59. Fioredda F, Iacobelli S, van Biezen A, et al. Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood 2015; 126:1885.
  60. Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Am J Hematol 2012; 87:238.
  61. ZUELZER WW. "MYELOKATHEXIS"--A NEW FORM OF CHRONIC GRANULOCYTOPENIA. REPORT OF A CASE. N Engl J Med 1964; 270:699.
  62. O'Regan S, Newman AJ, Graham RC. 'Myelokathexis'. Neutropenia with marrow hyperplasia. Am J Dis Child 1977; 131:655.
  63. Mamlok RJ, Juneja HS, Elder FF, et al. Neutropenia and defective chemotaxis associated with binuclear, tetraploid myeloid-monocytic leukocytes. J Pediatr 1987; 111:555.
  64. Plebani A, Cantù-Rajnoldi A, Collo G, et al. Myelokathexis associated with multiple congenital malformations: immunological study on phagocytic cells and lymphocytes. Eur J Haematol 1988; 40:12.
  65. Rassam SM, Roderick P, al-Hakim I, Hoffbrand AV. A myelokathexis-like variant of myelodysplasia. Eur J Haematol 1989; 42:99.
  66. Aprikyan AA, Liles WC, Park JR, et al. Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression of bcl-x in neutrophil precursors. Blood 2000; 95:320.
  67. Pasquet M, Bellanné-Chantelot C, Tavitian S, et al. High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood 2013; 121:822.
  68. Fenske CD, Jeffery S, Weber JL, et al. Localisation of the gene for glycogen storage disease type 1c by homozygosity mapping to 11q. J Med Genet 1998; 35:269.
  69. Annabi B, Hiraiwa H, Mansfield BC, et al. The gene for glycogen-storage disease type 1b maps to chromosome 11q23. Am J Hum Genet 1998; 62:400.
  70. Kuijpers TW, Maianski NA, Tool AT, et al. Apoptotic neutrophils in the circulation of patients with glycogen storage disease type 1b (GSD1b). Blood 2003; 101:5021.
  71. Leuzzi R, Bánhegyi G, Kardon T, et al. Inhibition of microsomal glucose-6-phosphate transport in human neutrophils results in apoptosis: a potential explanation for neutrophil dysfunction in glycogen storage disease type 1b. Blood 2003; 101:2381.
  72. Fowler B. Genetic defects of folate and cobalamin metabolism. Eur J Pediatr 1998; 157 Suppl 2:S60.
  73. Farrar JE, Rohrer J, Conley ME. Neutropenia in X-linked agammaglobulinemia. Clin Immunol Immunopathol 1996; 81:271.
  74. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood 2007; 109:93.
  75. Link DC, Kunter G, Kasai Y, et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood 2007; 110:1648.
  76. Ancliff PJ, Gale RE, Liesner R, et al. Long-term follow-up of granulocyte colony-stimulating factor receptor mutations in patients with severe congenital neutropenia: implications for leukaemogenesis and therapy. Br J Haematol 2003; 120:685.
  77. Bernard T, Gale RE, Evans JP, Linch DC. Mutations of the granulocyte-colony stimulating factor receptor in patients with severe congenital neutropenia are not required for transformation to acute myeloid leukaemia and may be a bystander phenomenon. Br J Haematol 1998; 101:141.
  78. Hunter MG, Avalos BR. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. Blood 2000; 95:2132.
  79. Smith OP, Reeves BR, Kempski HM, Evans JP. Kostmann's disease, recombinant HuG-CSF, monosomy 7 and MDS/AML. Br J Haematol 1995; 91:150.
  80. Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000; 96:429.
  81. Rosen RB, Kang SJ. Congenital agranulocytosis terminating in acute myelomonocytic leukemia. J Pediatr 1979; 94:406.
  82. Gilman PA, Jackson DP, Guild HG. Congenital agranulocytosis: prolonged survival and terminal acute leukemia. Blood 1970; 36:576.